← ACTUATE THERAPEUTICS, INC. (ACTU) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
ACTUATE THERAPEUTICS, INC. (ACTU)
Pharmaceutical Preparations · market cap $20M · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Actuate Therapeutics (ACTU) is a micro-cap clinical-stage pharmaceutical company with a market cap of ~$41M and only 10 employees, focused on oncology. Its lead asset is ruxolitinib in Phase 2 for myelofibrosis, and it is also advancing 9-ING-41 in Phase 2 for cancer. The company has ~$8.1M in cash, implying a runway of approximately 4.9 months, making near-term financing a critical overhang.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
- 2026-12-31 (est.)Phase 2 · FOLFIRNINOXimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| 9-ING-41 | Phase 2 | Cancer |
| FOLFIRNINOX | Phase 2 | Pancreatic Adenocarcinoma |
| Carboplatin | Phase 2 | Salivary Gland Cancer |
Price & technical context
3-month
-40.0%
6-month
-66.1%
12-month
-87.9%
52-wk range
$0.62–$8.09
vs 50-day MA
-24.5%
vs 200-day MA
-69.3%
Realized vol
105.5%
Max drawdown
-94.8%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ACTU (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.